New Avenues for the Treatment of Huntington's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a fatal, inherited neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene.
• Pathologically, HD is characterized by progressive neurodegeneration in the striatum and cortex, leading to motor, cognitive, and psychiatric impairments.
• While the genetic cause is known, the complex mechanisms driving neurodegeneration necessitate diverse therapeutic strategies.

Purpose of the Study:

• To provide a comprehensive review of current and emerging therapeutic strategies for Huntington's disease.
• To summarize approved treatments and ongoing clinical trials for HD symptom management and disease modification.
• To discuss promising pre-clinical disease-modifying approaches for Huntington's disease.

Main Methods:

• Literature review of approved HD treatments.
• Analysis of ongoing clinical trials for Huntington's disease.
• Synthesis of pre-clinical research on novel therapeutic targets and modalities.

Main Results:

• Current treatments primarily manage HD symptoms, with ongoing trials exploring various targets.
• Significant pre-clinical progress is being made in disease-modifying strategies.
• Promising avenues include neurotrophic support, autophagy modulation, genetic/epigenetic interventions, and cell-based therapies.

Conclusions:

• While symptomatic treatments offer quality of life improvements, disease-modifying therapies are crucial for Huntington's disease.
• Pre-clinical research shows significant promise for novel strategies targeting underlying disease mechanisms.
• Continued investment in both clinical trials and fundamental research is essential for developing effective HD treatments.